We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Research Reveals PET Effectively Identifies Dementia

By MedImaging International staff writers
Posted on 18 Jan 2012
Print article
In a new report of imaging studies covering more than 10 years, scientists revealed that a positron emission tomography (PET) imaging technique safely and effectively identifies dementia, including the most typical and debilitating form affecting older individuals, Alzheimer’s disease.

The study’s findings were published in the January 2012 issue of the Journal of Nuclear Medicine. Researchers reviewed many PET studies to assess a molecular imaging technique that combines PET, which provides functional images of biologic mechanisms, with an injected biomarker called 18F-FDG to target major areas of metabolic decrease in the brain indicating dementia. Having physiologic evidence of neurodegenerative disease by imaging patients with PET could provide clinicians with the data they need to make more accurate diagnoses earlier than ever before.

“The new data support the role of 18F-FDG PET as an effective addition to other diagnostic methods used to assess patients with symptoms of dementia,” commented Nicolaas Bohnen, MD, PhD, lead author of the study and professor of radiology and neurology at the University of Michigan (Ann Arbor, MI, USA). “The review also identified new literature showing the benefit of this imaging technique for not only helping to diagnose dementia but also for improving physician confidence when diagnosing a patient with dementia. This process can be difficult for physicians, especially when evaluating younger patients or those who have subtle signs of disease.”

Dementia is not a specific disease but a pattern of symptoms characterized by a loss of cognitive ability. These disorders can be caused by injury or progressive disease affecting regions of the brain that regulate attention, memory, language, and mobility. Whereas Alzheimer’s is most typically associated with progressive memory impairment, dementia with Lewy bodies, another form of the disease, can be associated with symptoms of Parkinson’s and prominent hallucinations, while another disorder, called frontotemporal dementia, can be seen in patients showing abnormal personality changes and problems in communicating and relating. Physicians can use FDG-PET with high accuracy to not only help diagnose dementia but also differentiate between the individual disorders. The role molecular imaging plays in the diagnosis of dementia has expanded enough that the official principles physicians use to diagnose patients now includes evidence from molecular imaging studies.

“For the first time, imaging biomarkers of Alzheimer’s disease are included in the newly revised clinical diagnostic criteria for the disease,” said Dr. Bohnen. “This is a major shift in disease definition, as previously an Alzheimer’s diagnosis was based mainly on a process of evaluating patients to exclude possible trauma, hemorrhage, tumor, or metabolic disorder. Now it is becoming a process of inclusion based on biomarker evidence from molecular imaging.”

The PET biomarker 18F-FDG comprises a radionuclide combined with fluorodeoxyglucose (FDG), which mimics glucose in the body. Cells metabolize FDG as fuel, and the variation in this uptake by cells throughout the body can then be imaged to identify a range of abnormalities. In the instance of dementia, marked reductions in the metabolism of different lobes of the cerebral cortex can confirm a disorder. Physicians can differentiate Alzheimer’s disease from other dementias, depending on the specific cortices affected.

This study, according to the investigators, represents the newest and most significant evidence of FDG-PET’s effectiveness for the assessment of patients with suspected dementia. The goal of the study was to replace earlier retrospective reviews that were performed as the technique was just emerging and that suggested methodologic improvements. The new review includes studies with better methodology, including validation of diagnoses with autopsy, more expansive recruitment of subjects, and use of multicenter studies. After reviewing 11 studies that occurred since the year 2000 and that met more stringent study review standards, researchers concluded that 18F-FDG is very effective for detecting the presence and type of dementia.

“Using 18F-FDG PET in the evaluation of patients with dementia can improve diagnostic accuracy and lead to earlier treatment and better patient care,” said Dr. Bohnen. “The earlier we make a diagnosis, the more we can alleviate uncertainty and suffering for patients and their families."

The biomarker 18F-FDG is among a range of imaging agents being studied for its effectiveness in Alzheimer’s imaging. As dementia treatments become available for clinical use, PET should play a significant role in not only the diagnosis of these diseases, but also the assessment and monitoring of future therapies.

According to the World Health Organization (Geneva, Switzerland), an estimated 18 million people worldwide are currently living with Alzheimer disease. That number is projected to nearly double by 2025.

Related Links:
University of Michigan



Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
X-Ray Detector
FDR-D-EVO III
New
Thyroid Shield
Standard Thyroid Shield
Ultrasound System
P25 Elite

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

General/Advanced Imaging

view channel
Image: The Cinematic Reality app enables interaction with realistic renderings of human anatomy (Photo courtesy of Siemens)

AR Application Turns Medical Scans Into Holograms for Assistance in Surgical Planning

Siemens Healthineers (Erlangen, Germany) has launched an app designed for Apple Vision Pro that allows users including surgeons, medical students, or patients to view immersive, interactive holograms of... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.